Hexarelin
Also known as: Examorelin
Six-amino-acid ghrelin mimetic that raises GH, studied for heart effects in animals.
Evidence
Moderate
FDA status
Not FDA-approved
Source
Synthetic hexapeptide ghrelin mimetic
Overview
Six-amino-acid ghrelin mimetic that raises GH, studied for heart effects in animals.
Mechanism of Action
Binds GHS-R1a ghrelin receptor with high affinity, raises GH, also binds CD36 receptor for cardioprotection independent of GH, may desensitize with chronic use.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- GH release
- Heart effects in animal models
- Increased muscle mass
- Enhanced recovery
- Improved bone density
- Neuroprotection
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Hexarelin isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Clinical trials, preclinical cardioprotection research
Human studies show it raises GH, with the effect fading over time. Heart effects through the CD36 receptor are reported in animal models.
Safety Information
Potential Side Effects
- •Increased hunger
- •Water retention
- •Cortisol elevation (mild)
- •Desensitization with prolonged use
Contraindications
- Active cancer
- Pregnancy
- Breastfeeding
Interactions
- ⚠Synergistic with GHRH analogs
Quick Facts
Related Peptides
CJC-1295
Long-acting GHRH analog that stimulates sustained growth hormone release.
Ipamorelin
Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.
Tesamorelin
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.